Skip to main content

Advertisement

SpringerLink
Log in

Risk of hospitalization for common neonatal morbidities in preterm and term infants: assessing the impact of one or more major congenital anomalies

  • Article
  • Published:
Journal of Perinatology Submit manuscript

Abstract

Objective

To analyze the impact of ≥1 major congenital anomaly (CA) on risk and hospitalization for common neonatal morbidities.

Study Design

Retrospective infant cohort: 241,033 preterm and 3,446,156 term singletons in the US Premier Healthcare database (2006–2013) with up to 1-year follow-up. Discharge records were searched for ≥1 CA and neonatal morbidities.

Results

Five morbidities demonstrated strong increasing rates as GA decreased. RRs in preterm infants with CAs relative to those without CAs were: RDS (2.17, 95% CI 2.14–2.21), sepsis (2.42, 95% CI 2.37–2.46), apnea (2.04, 95% CI 2.01–2.07), infectious diseases (2.37, 95% CI 2.34–2.41), and hyperbilirubinemia (1.25, 95% CI 1.24–1.26). Median length of NICU stay (days) was consistently longer in infants with ≥1 CA relative to infants without CA during each GA period.

Conclusions

Preterm infants with ≥1 major CA have increased risk of hospitalization for common morbidities, implying compromised neonatal health regardless of CA type.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379:2162–72.

    Article  Google Scholar 

  2. MacDorman MF, Matthews TJ, Mohangoo AD, Zeitlin J. International comparisons of infant mortality and related factors: United States and Europe, 2010. Natl Vital- Stat Rep. 2014;63:1–6.

    PubMed  Google Scholar 

  3. Martin JA, Hamilton BE, Osterman MJ, Driscoll AK, Mathews TJ. Births: final data for 2015. Natl Vital- Stat Rep. 2017;66:1.

    PubMed  Google Scholar 

  4. Martin JA, Hamilton BE, Osterman MJK, Driscoll AK, Drake P. Births: final data for 2016. Natl Vital- Stat Rep. 2018;67:1–55.

    PubMed  Google Scholar 

  5. Ancel PY, Goffinet F, Group E-W, Kuhn P, Langer B, Matis J, et al. Survival and morbidity of preterm children born at 22 through 34 weeks’ gestation in France in 2011: results of the EPIPAGE-2 cohort study. JAMA Pediatr. 2015;169:230–8.

    Article  Google Scholar 

  6. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008;371:261–9.

    Article  Google Scholar 

  7. Khashu M, Narayanan M, Bhargava S, Osiovich H. Perinatal outcomes associated with preterm birth at 33 to 36 weeks’ gestation: a population-based cohort study. Pediatrics. 2009;123:109–13.

    Article  Google Scholar 

  8. Altman M, Vanpee M, Cnattingius S, Norman M. Neonatal morbidity in moderately preterm infants: a Swedish national population-based study. J Pediatr. 2011;158:239–44 e1.

    Article  Google Scholar 

  9. Platt MJ. Outcomes in preterm infants. Public Health. 2014;128:399–403.

    Article  CAS  Google Scholar 

  10. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010;126:443–56.

    Article  Google Scholar 

  11. Pimenta JM, Ebeling M, Montague TH, Beach KJ, Abell J, O’Shea MT, et al. A retrospective database analysis of neonatal morbidities to evaluate a composite endpoint for use in preterm labor clinical trials. AJP Rep. 2018;8:e25–e32.

    Article  Google Scholar 

  12. Walsh MC, Bell EF, Kandefer S, Saha S, Carlo WA, D’Angio CT, et al. Neonatal outcomes of moderately preterm infants compared to extremely preterm infants. Pediatr Res. 2017;82:297–304.

    Article  Google Scholar 

  13. American Academy of Pediatrics, Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114:297–316.

    Article  Google Scholar 

  14. Polin RA. Committee on Fetus Newborn. Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics. 2012;129:1006–15.

    Article  Google Scholar 

  15. Henderson-Smart DJ. The effect of gestational age on the incidence and duration of recurrent apnoea in newborn babies. Aust Paediatr J. 1981;17:273–6.

    CAS  PubMed  Google Scholar 

  16. Matthews TJ, MacDorman MF, Thoma ME. Infant mortality statistics from the 2013 period linked birth/infant death data set. Natl Vital- Stat Rep. 2015;64:1–30.

    CAS  PubMed  Google Scholar 

  17. Honein MA, Kirby RS, Meyer RE, Xing J, Skerrette NI, Yuskiv N, et al. The association between major birth defects and preterm birth. Matern Child Health J. 2009;13:164–75.

    Article  Google Scholar 

  18. Linhart Y, Bashiri A, Maymon E, Shoham-Vardi I, Furman B, Vardi H, et al. Congenital anomalies are an independent risk factor for neonatal morbidity and perinatal mortality in preterm birth. Eur J Obstet Gynecol Reprod Biol. 2000;90:43–9.

    Article  CAS  Google Scholar 

  19. Werler MM. Congenital malformations and consequential epidemiology. Curr Epidemiol Rep. 2015;2:8–12.

    Article  Google Scholar 

  20. Bateman BT, Huybrechts KF, Hernandez-Diaz S, Liu J, Ecker JL, Avorn J. Methylergonovine maleate and the risk of myocardial ischemia and infarction. Am J Obstet Gynecol. 2013;209:459e1–e13.

    Article  Google Scholar 

  21. Pokras SM, Petrilla AA, Weatherall J, Lee WC. The economics of inpatient on-demand treatment for haemophilia with high-responding inhibitors: a US retrospective data analysis. Haemophilia. 2012;18:284–90.

    Article  CAS  Google Scholar 

  22. Delnord M, Hindori-Mohangoo AD, Smith LK, Szamotulska K, Richards JL, Deb-Rinker P, et al. Variations in very preterm birth rates in 30 high-income countries: are valid international comparisons possible using routine data? BJOG. 2016;124:785–94.

    Article  Google Scholar 

  23. Correa A, Cragan JD, Kucik JE, Alverson CJ, Gilboa SM, Balakrishnan R, et al. Reporting birth defects surveillance data 1968-2003. Birth Defects Res A Clin Mol Teratol. 2007;79:65–186. https://www.cdc.gov/ncbddd/birthdefects/macdp.html.

    CAS  PubMed  Google Scholar 

  24. Sullivan L. Essential of biostatistics in public health. 2nd edn. Sudbury: Jones and Bartlett Learning; 2012. p. 202.

  25. Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA. 2015;314:1039–51.

    Article  CAS  Google Scholar 

  26. Loftin RW, Habli M, Snyder CC, Cormier CM, Lewis DF, Defranco EA. Late preterm birth. Rev Obstet Gynecol. 2010;3:10–9.

    PubMed  PubMed Central  Google Scholar 

  27. Ratra D, Akhundova L, Das MK. Retinopathy of prematurity like retinopathy in full-term infants. Oman J Ophthalmol. 2017;10:167–72.

    Article  Google Scholar 

Download references

Funding

The design and conduct of this study was funded by GlaxoSmithKline (GSK study ID: HO-13-7277). The authors were not compensated by GSK for the preparation of this publication.

Author information

Authors and Affiliations

  1. ECC Population Health Group, St. Petersburg, FL, USA

    Janet R. Hardy

  2. University of South Florida College of Public Health, Tampa, FL, USA

    Janet R. Hardy

  3. GlaxoSmithKline, Value Evidence & Outcomes (Epidemiology), Stockley Park, Middlesex, Uxbridge, UK

    Jeanne M. Pimenta

  4. GlaxoSmithKline, Value Evidence & Outcomes, GSK, Collegeville, PA, USA

    Shibani Pokras

  5. Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, USA

    Harish Sehdev

  6. GlaxoSmithKline, Real World Data & Analytics, GSK, Waltham, MA, USA

    Samantha St. Laurent

  7. GlaxoSmithKline, Value Evidence & Outcomes, GSK, Research Triangle Park, NC, USA

    Libby Black

  8. Recro Pharma Inc, Malvern, PA, USA

    Libby Black

  9. The Warren Alpert Medical School of Brown University, Providence, RI, USA

    Mara Coyle

Authors
  1. Janet R. Hardy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeanne M. Pimenta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shibani Pokras
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Harish Sehdev
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Samantha St. Laurent
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Libby Black
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mara Coyle
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Drs. Hardy, Pimenta, Sehdev, Black, and Coyle, and Ms. Pokras conceptualized and designed the study. Dr. Black and Ms. St. Laurent were responsible for data acquisition. All authors were responsible for the analysis or interpretation of data. Dr. Hardy drafted and revised the paper. All authors critically reviewed the paper for important intellectual content. All authors approved the final paper as submitted and agree to be accountable for all aspects of the work. Dr. Hardy obtained funding for this project.

Corresponding author

Correspondence to Janet R. Hardy.

Ethics declarations

Conflict of interest

JMP, SP, and SSL are employees and shareholders of GlaxoSmithKline. LB is a GSK shareholder, and was a GSK employee and GSK contractor during this project. JRH is an employee of ECCPH. ECCPH received funding from GSK in support of the design and conduct of this study (GSK study HO-13-7277). MC and HS have nothing to disclose. The authors were not compensated by GSK for the preparation of this publication.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hardy, J.R., Pimenta, J.M., Pokras, S. et al. Risk of hospitalization for common neonatal morbidities in preterm and term infants: assessing the impact of one or more major congenital anomalies. J Perinatol 39, 1602–1610 (2019). https://doi.org/10.1038/s41372-019-0460-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41372-019-0460-4

  • Springer Nature America, Inc.

Search

Navigation